Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Glioblastoma 8Breast Neoplasms 7Prostatic Neoplasms 6Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 5Glioma 5Astrocytoma 5Oropharyngeal Neoplasms 4Esophageal Neoplasms 4Carcinoma 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Rectal Neoplasms 3Neoplasm Metastasis 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Pancreatic Neoplasms 2Neoplasms 2Mouth Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Liposarcoma 2Laryngeal Neoplasms 2Hodgkin Disease 2Gliosarcoma 2Ganglioneuroblastoma 2

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Alveolar × Radiation × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡